Finance

Lists
TENX:NASDAQ
Tenax Therapeutics Inc
$1.88
+1.07%
(+0.020) 1D
Sep 14, 12:24:28 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TENX...
Open
$1.84
High
$1.88
Low
$1.83
Mkt. cap
70.35M
Avg. vol.
9.39M
Volume
789.88K
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.47
Beta
0.83
Shares outstanding
37.42M
No. of employees
15
Open
$1.84
High
$1.88
Low
$1.83
Mkt. cap
70.35M
Avg. vol.
9.39M
Volume
789.88K
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.47
Beta
0.83
Shares outstanding
37.42M
No. of employees
15
News stories
From web sources and news partners
About Tenax Therapeutics Inc
CEOChris Giordano
Employees15
Founded1967
Headquarters-
SectorBiotechnology
Websitetenaxthera.com
Analyst ratings
Based on 10 analysts giving stock ratings to TENX in the past 3 months
Buy
Buy
6
Hold
4
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TENX in the last 3 months.
Highest
Current $1.88
$35.00 (+1,761.80%)
Average
$9.63 (+412.26%)
Lowest
$4.00 (+112.78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$35.00
+1,761.8%
09/09/2026
Angela Qian
Canaccord Genuity
Buy
Maintained
$4.00
+112.8%
08/31/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$14.00
+644.7%
08/31/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/31/2026
Seamus Fernandez
Guggenheim
Hold
Downgraded
-
-
08/31/2026
Gautam Chukka
Chardan Capital
Hold
Downgraded
$5.00
+166%
08/11/2026
David Risinger
Leerink Partners
Buy
Maintained
$4.00
+112.8%
08/11/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$5.00
+166%
08/10/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
$5.00
+166%
08/10/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
$5.00
+166%
08/10/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$35.00
+1,761.8%
07/28/2026
Unknown Analyst
Chardan Capital
Buy
Initiated
$27.00
+1,336.2%
06/22/2026
Unknown Analyst
Roth MKM
Buy
Maintained
$30.00
+1,495.8%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.33M
10.54M
11.54M
12.85M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.48M
5.91M
5.03M
5.93M
Operating expense
16.81M
16.45M
16.57M
18.78M
Total operating expenses
16.81M
16.45M
16.57M
18.78M
Operating income
-16.81M
-16.45M
-16.57M
-18.78M
Other non operating income
-15.00K
-9.00K
-4.00K
-
EBT including unusual items
-15.80M
-15.54M
-15.72M
-17.80M
EBT excluding unusual items
-15.80M
-15.54M
-15.72M
-17.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.80M
-15.54M
-15.72M
-17.80M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.38
-0.35
-0.35
Interest and investment income
1.02M
918.00K
861.00K
981.00K
Interest expense
-
-
-
-
Net interest expenses
1.02M
918.00K
861.00K
981.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps